Constitutive Activity at the Cannabinoid CB1Receptor Is Required for Behavioral Response to Noxious Chemical Stimulation of TRPV1: Antinociceptive Actions of CB1 Inverse Agonists
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The potential modulation of TRPV1 nociceptive activity by the CB 1 receptor was investigated here using CB 1 wild-type (WT) and knock-out (KO) mice as well as selective CB 1 inverse agonists. No significant differences were detected in baseline thermal thresholds of ICR, CB 1 WT or CB 1 KO mice. Intraplantar capsaicin produced dose- and time-related paw flinch responses in ICR and CB 1 WT mice and induced plasma extravasation yet minimal responses were seen in CB 1 KO animals with no apparent differences in TRPV1 channel expression. Capsaicin-evoked CGRP release from spinal cord tissue and capsaicin-evoked action potentials on isolated skin-nerve preparation were significantly decreased in CB 1 KO mice. Pretreatment with intraplantar galanin and bradykinin, compounds known to sensitize TRPV1 receptors, restored capsaicin-induced flinching in CB 1 KO mice. The possibility that constitutive activity at the CB 1 receptor is required to maintain the TRPV1 receptor in a “sensitized” state was tested using CB 1 inverse agonists. The CB 1 inverse agonists elicited concentration-related inhibition of capsaicin-induced calcium influx in F-11 cells and produced dose-related inhibition of capsaicin-induced flinching in ICR mice. These data suggest that constitutive activity at the CB 1 receptor maintains the TRPV1 channel in a sensitized state responsive to noxious chemical stimuli. Treatment with CB 1 inverse agonists may promote desensitization of the channel resulting in antinociceptive actions against chemical stimulus modalities. These studies propose possible therapeutic exploitation of a novel mechanism providing pain relief by CB 1 inverse agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impaired nociception and pain sensation in mice lacking the capsaicin receptor
Caterina, M. J., Leffler, A., Malmberg, A. B., Martin, W. J., Trafton, J., Petersen-Zeitz, K. R., Koltzenburg, M., Basbaum, A. I., & Julius, D. (2000) · Science · doi:10.1126/science.288.5464.306 · Cited by 3,544
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142 · cited 5×
“Since the discovery that the CB1 agonist anandamide (AEA) could also activate TRPV1 (Zygmunt et al., 1999; Smart et al., 2000), a barrage of investigations has focused on the relationship between these receptors, particularly in C-fibers, in which activation of TRPV1 and CB1 receptor lead to…”
BackgroundInfluentialEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 4×
“In clinical studies, Rimonabant has resulted in weight loss, reduction in low-density lipoproteins, and decrease in craving of cigarette smoking suggesting a significant tonic activation of CB1 receptors (Després et al., 2005; Huestis et al., 2007).”
BackgroundInfluentialThe endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., Chambers, J. K., Randall, A. D., & Davis, J. B. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703050 · Cited by 775
TRPV1 Channels Mediate Long-Term Depression at Synapses on Hippocampal Interneurons
Gibson, H. E., Edwards, J. G., Page, R. S., Van Hook, M. J., & Kauer, J. A. (2008) · Neuron · doi:10.1016/j.neuron.2007.12.027 · Cited by 388 · cited 2×
“Although it has been reported that SR141716A may act directly at the TRPV1 channel in concentrations 1 M (De Petrocellis et al., 2001; Gibson et al., 2008), our in vitro studies used SR141716A at concentrations 10- to 100-fold lower, suggesting that this ligand is acting selectively at CB1…”
BackgroundMitrirattanakul, S., Ramakul, N., Guerrero, A. V., Matsuka, Y., Ono, T., Iwase, H., Mackie, K., Faull, K. F., & Spigelman, I. (2006) · Pain · doi:10.1016/j.pain.2006.06.016 · Cited by 207 · cited 2×
“Recent reports demonstrate the expression of CB1 and TRPV1 proteins on the same cells (Ahluwalia et al., 2000, 2002; Binzen et al., 2006; Mitrirattanakul et al., 2006) providing an anatomical basis for modulation of TRPV1 function by compounds interacting at the CB1 receptor.”
BackgroundGavva, N. R., Bannon, A. W., Hovland, D. N., Lehto, S. G., Klionsky, L., Surapaneni, S., Immke, D. C., Henley, C., Arik, L., Bak, A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.125674 · Cited by 180 · cited 1×
“…development of TRPV1 antagonists for acute and inflammatory pain have resulted in some unwanted side effects including increasing body temperature (Gavva et al., 2007) and some uncertainty in such antagonists for drug development, yet a very recent study by the same group reported TRPV1…”
BackgroundCosta, B., Trovato, A. E., Colleoni, M., Giagnoni, G., Zarini, E., & Croci, T. (2005) · Pain · doi:10.1016/j.pain.2005.03.043 · Cited by 104
Cited by
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis
Hammell, D. C., Zhang, L. P., Ma, F., Abshire, S. M., McIlwrath, S. L., Stinchcomb, A. L., & Westlund, K. N. (2016) · European Journal of Pain · doi:10.1002/ejp.818 · Cited by 300
Why do cannabinoid receptors have more than one endogenous ligand?
Di Marzo, V., & De Petrocellis, L. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0382 · Cited by 290
Paracetamol – An old drug with new mechanisms of action
Przybyła, G. W., Szychowski, K. A., & Gmiński, J. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13392 · Cited by 190
Metadata
- Authors
- Fioravanti, B., De Felice, M., Stucky, C. L., Medler, K. A., Luo, M.-C., Gardell, L. R., Ibrahim, M., Malan, T. P., Yamamura, H. I., Ossipov, M. H., King, T., Lai, J., Porreca, F., & Vanderah, T. W.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2008-11-05
- Volume
- 28
- Issue
- 45
- Pages
- 11593-11602
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2092429112
- Cited by
- 85
- References
- 8
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Constitutive Activity at the Cannabinoid CB1Receptor Is Required for Behavioral Response to Noxious Chemical Stimulation of TRPV1: Antinociceptive Actions of CB1 Inverse Agonists. https://app.cochat.ai/papers/10.1523/jneurosci.3322-08.2008
- The paper
- Fioravanti, B., De Felice, M., Stucky, C. L., Medler, K. A., Luo, M.-C., Gardell, L. R., Ibrahim, M., Malan, T. P., Yamamura, H. I., Ossipov, M. H., King, T., Lai, J., Porreca, F., & Vanderah, T. W. (2008). Constitutive Activity at the Cannabinoid CB1Receptor Is Required for Behavioral Response to Noxious Chemical Stimulation of TRPV1: Antinociceptive Actions of CB1 Inverse Agonists. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.3322-08.2008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.